KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Convertible Debt (2016 - 2026)

Ionis Pharmaceuticals has reported Convertible Debt over the past 18 years, most recently at $568.5 million for Q1 2026.

  • For Q1 2026, Convertible Debt changed 0.5% year-over-year to $568.5 million; the TTM value through Mar 2026 reached $568.5 million, changed 0.5%, while the annual FY2025 figure was $567.8 million, 0.5% changed from the prior year.
  • Convertible Debt for Q1 2026 was $568.5 million at Ionis Pharmaceuticals, roughly flat from $567.8 million in the prior quarter.
  • Over five years, Convertible Debt peaked at $627.7 million in Q3 2024 and troughed at $114.1 million in Q2 2023.
  • A 5-year average of $562.0 million and a median of $568.5 million in 2026 define the central range for Convertible Debt.
  • Biggest five-year swings in Convertible Debt: tumbled 81.62% in 2023 and later surged 394.08% in 2024.
  • Year by year, Convertible Debt stood at $622.2 million in 2022, then dropped by 9.64% to $562.3 million in 2023, then grew by 0.49% to $565.0 million in 2024, then rose by 0.5% to $567.8 million in 2025, then rose by 0.13% to $568.5 million in 2026.
  • Business Quant data shows Convertible Debt for IONS at $568.5 million in Q1 2026, $567.8 million in Q4 2025, and $565.7 million in Q1 2025.